Literature DB >> 33478150

Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.

Michal Kielbik1, Izabela Szulc-Kielbik1, Magdalena Klink1.   

Abstract

It has been increasingly recognized that SNAIL1 and SNAIL2, as major EMT-inducers, might also be involved in drug resistance of cancer cells. We sought to determine a relation between SNAIL1/2, E-cadherin and N-cadherin expression, as well as ovarian cancer cells' resistance to cisplatin and EMT markers' level. Thus, four ovarian cancer cell lines, were used: A2780, A2780cis, SK-OV-3 and OVCAR-3. We assessed the impact of ERK1/2, AKT and STAT3 proteins (chosen by the profiling activity of over 40 signaling proteins) on SNAIL1/2 expression, along with E-cadherin and N-cadherin levels. We showed that expression of SNAIL1 and N-cadherin are the highest in cisplatin-resistant A2780cis and SK-OV-3 cells, while high SNAIL2 and E-cadherin levels were observed in cisplatin-sensitive A2780 cells. The highest E-cadherin level was noticed in OVCAR-3 cells. SNAIL1/2 expression was dependent on ERK1/2 activity in cisplatin-resistant and potentially invasive SK-OV-3 and OVCAR-3 cells. STAT-3 regulates expression of SNAIL1/2 and leads to the so-called "cadherin switch" in cancer cells, independently of their chemoresistance. In conclusion, SNAIL1, but not SNAIL2, seems to be involved in ovarian cancer cells' cisplatin resistance. STAT3 is a universal factor determining the expression of SNAIL1/2 in ovarian cancer cells regardless of their chemoresitance or invasive capabilities.

Entities:  

Keywords:  SNAIL 1; SNAIL 2; cadherins; chemoresistance; ovarian cancer; signaling proteins

Year:  2021        PMID: 33478150      PMCID: PMC7835952          DOI: 10.3390/ijms22020980

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  64 in total

1.  Piperine inhibits colorectal cancer migration and invasion by regulating STAT3/Snail-mediated epithelial-mesenchymal transition.

Authors:  Lingyu Song; Yan Wang; Yunhuan Zhen; Dengke Li; Xidong He; Hong Yang; Huayang Zhang; Qi Liu
Journal:  Biotechnol Lett       Date:  2020-06-04       Impact factor: 2.461

2.  Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.

Authors:  Dennis Shin-Shian Hsu; Hsin-Yi Lan; Chi-Hung Huang; Shyh-Kuan Tai; Shyue-Yih Chang; Tung-Lung Tsai; Cheng-Chi Chang; Cheng-Hwai Tzeng; Kou-Juey Wu; Jung-Yie Kao; Muh-Hwa Yang
Journal:  Clin Cancer Res       Date:  2010-09-07       Impact factor: 12.531

3.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Authors:  Alexandria M Haslehurst; Madhuri Koti; Moyez Dharsee; Paulo Nuin; Ken Evans; Joseph Geraci; Timothy Childs; Jian Chen; Jieran Li; Johanne Weberpals; Scott Davey; Jeremy Squire; Paul C Park; Harriet Feilotter
Journal:  BMC Cancer       Date:  2012-03-19       Impact factor: 4.430

4.  STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells.

Authors:  Yanhui Ma; Xiaolei Zhang; Xiaoxuan Xu; Liang Shen; Yao Yao; Ziyan Yang; Peishu Liu
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

Review 5.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

6.  Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.

Authors:  Junli Deng; Xupeng Bai; Xiaojie Feng; Jie Ni; Julia Beretov; Peter Graham; Yong Li
Journal:  BMC Cancer       Date:  2019-06-24       Impact factor: 4.430

Review 7.  PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.

Authors:  Alia Ghoneum; Neveen Said
Journal:  Cancers (Basel)       Date:  2019-07-05       Impact factor: 6.639

8.  MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM.

Authors:  Hong-Yun Liu; Yu-Ying Zhang; Bao-Lian Zhu; Fu-Zhong Feng; Hai-Tang Zhang; Hua Yan; Bin Zhou
Journal:  J Ovarian Res       Date:  2019-07-05       Impact factor: 4.234

Review 9.  Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.

Authors:  Sudeep Gupta; Shona Nag; Shyam Aggarwal; Amit Rauthan; Narayanankutty Warrier
Journal:  J Ovarian Res       Date:  2019-11-04       Impact factor: 4.234

Review 10.  New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.

Authors:  Anushka Dongre; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2019-02       Impact factor: 94.444

View more
  3 in total

1.  Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.

Authors:  Yadong Liu; Huiyan Lv; Xingyi Li; Jiannan Liu; Song Chen; Yaodong Chen; Yinshan Jin; Ruihua An; Shiliang Yu; Zhigang Wang
Journal:  Int J Biol Sci       Date:  2021-08-13       Impact factor: 6.580

2.  Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.

Authors:  Yaman Alghamian; Chadi Soukkarieh; Abdul Qader Abbady; Hossam Murad
Journal:  Sci Rep       Date:  2022-05-06       Impact factor: 4.996

3.  Super-Enhancer Induced IL-20RA Promotes Proliferation/Metastasis and Immune Evasion in Colorectal Cancer.

Authors:  Dingye Yu; Xiao Yang; Jianwei Lin; Zichao Cao; Chenghao Lu; Zheyu Yang; Minhua Zheng; Ruijun Pan; Wei Cai
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.